Division of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, No. 37 Guoxue Lane, Chengdu, 610041, Sichuan, China.
Institute of Digestive Surgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital Sichuan University, No. 37 Guoxue Lane, Chengdu, 610041, Sichuan, China.
Updates Surg. 2024 Oct;76(6):2151-2162. doi: 10.1007/s13304-024-01876-6. Epub 2024 May 17.
To compare the short-term outcomes and explore the potential economic benefits of laparoscopic-assisted colectomy with extracorporeal anastomosis (LAC/EA) vs. laparoscopic complete colectomy with intracorporeal anastomosis (LCC/IA) for patients with non-metastatic resectable colon cancer. Data of patients who underwent laparoscopic hemicolectomy from January 2017 to March 2023 were collected and analyzed. Propensity score matching (PSM) analyses was carried out to minimize the selection bias. Before PSM, a total of 113 patients met the inclusion criteria (39 in the LCC/IA vs. 74 in the LAC/EA). Clinicopathologic characteristics were comparable except for the median number of removed lymph nodes (P = 0.023). LCC/IA was associated with longer operative time, less intraoperative blood loss, and shorter incision length. The rate of 30-day postoperative complications was similar, but the time to first flatus and soft diet was shorter in the LCC/IA. No deaths were reported in either group within 30 days after surgery. Costs of surgical instruments (25,945.8 ± 1,918.0 vs. 23,551.9 ± 2,665.5 RMB; P < 0.01) were higher for the LCC/IA but overall costs were similar (LCC/IA, 43,220.0 ± 4,954.0 vs. LAC/EA, 41,269.2 ± 6,685.9 RMB; P = 0.112). After PSM, 38 patients in the LCC/IA and 63 patients in the LAC/EA were compared. LCC/IA was superior in terms of intraoperative blood loss, incision length, and postoperative functional recovery. There was an extra charge of 2385.0 RMB regarding surgical instruments in the LCC/IA but the overall cost did not reach statistical significance. LCC/IA is a feasible, safe, and cost-effective surgical treatment for patients with non-metastatic resectable colon cancer.
比较腹腔镜辅助结直肠切除术联合体外吻合(LAC/EA)与腹腔镜全结肠切除术联合腔内吻合(LCC/IA)治疗非转移性可切除结肠癌患者的短期疗效,并探讨其潜在的经济效益。收集 2017 年 1 月至 2023 年 3 月行腹腔镜半结肠切除术患者的临床资料并进行分析。采用倾向评分匹配(PSM)分析以最小化选择偏倚。PSM 前,共纳入 113 例符合条件的患者(LCC/IA 组 39 例,LAC/EA 组 74 例)。两组患者除中位清扫淋巴结数(P=0.023)外,临床病理特征具有可比性。LCC/IA 组手术时间较长,术中出血量较少,切口长度较短。两组术后 30 天并发症发生率相似,但 LCC/IA 组首次排气和开始软食时间更早。两组术后 30 天内均无死亡病例。LCC/IA 组手术器械费用(25945.8±1918.0 vs. 23551.9±2665.5 元;P<0.01)较高,但总费用相似(LCC/IA:43220.0±4954.0 vs. LAC/EA:41269.2±6685.9 元;P=0.112)。PSM 后,LCC/IA 组 38 例,LAC/EA 组 63 例。LCC/IA 组术中出血量、切口长度和术后功能恢复均优于 LAC/EA 组。LCC/IA 组手术器械费用增加 2385.0 元,但总费用无统计学差异。LCC/IA 是治疗非转移性可切除结肠癌患者的一种可行、安全且具有成本效益的手术治疗方法。